ID29471A - Terapi kombinasi untuk mengobati virus hepatitis b - Google Patents

Terapi kombinasi untuk mengobati virus hepatitis b

Info

Publication number
ID29471A
ID29471A IDW00200101179A ID20011179A ID29471A ID 29471 A ID29471 A ID 29471A ID W00200101179 A IDW00200101179 A ID W00200101179A ID 20011179 A ID20011179 A ID 20011179A ID 29471 A ID29471 A ID 29471A
Authority
ID
Indonesia
Prior art keywords
virus
combination
alternation
administering
directed
Prior art date
Application number
IDW00200101179A
Other languages
English (en)
Indonesian (id)
Inventor
Philip A Furman
George R Painter
David Barry
Franck Rousseau
Original Assignee
Triangle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Triangle Pharmaceuticals Inc filed Critical Triangle Pharmaceuticals Inc
Publication of ID29471A publication Critical patent/ID29471A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW00200101179A 1998-11-02 1999-11-02 Terapi kombinasi untuk mengobati virus hepatitis b ID29471A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10666498P 1998-11-02 1998-11-02

Publications (1)

Publication Number Publication Date
ID29471A true ID29471A (id) 2001-08-30

Family

ID=22312611

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101179A ID29471A (id) 1998-11-02 1999-11-02 Terapi kombinasi untuk mengobati virus hepatitis b

Country Status (15)

Country Link
US (3) US6528515B1 (de)
EP (3) EP1380303B1 (de)
JP (2) JP2002528508A (de)
KR (1) KR100632520B1 (de)
CN (3) CN1173705C (de)
AT (3) ATE287268T1 (de)
AU (1) AU1810600A (de)
CY (2) CY1108635T1 (de)
DE (3) DE69923338T2 (de)
DK (2) DK1380303T3 (de)
ES (3) ES2237189T3 (de)
ID (1) ID29471A (de)
IL (3) IL142910A0 (de)
PT (2) PT1380303E (de)
WO (1) WO2000025797A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142910A0 (en) * 1998-11-02 2002-04-21 Triangle Pharmaceuticals Inc Combination therapy to treat hepatitis b virus
WO2004000336A1 (en) * 2002-06-19 2003-12-31 Fideline Avian appeasing pheromones to decrease stress, anxiety and aggressiveness
KR20110031250A (ko) * 2002-07-15 2011-03-24 길리애드 사이언시즈, 인코포레이티드 B형 간염 바이러스 감염의 치료를 위한 l-fmau를 사용한 병용 치료
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
KR20100127180A (ko) * 2009-05-25 2010-12-03 부광약품 주식회사 클레부딘 및 아데포비어 디피복실을 함유하는 만성 b형 간염 치료용 조성물
PH12012502210A1 (en) * 2010-05-18 2013-02-04 Bukwang Pharma Co Ltd Composition for treating chronic hepatitis b, containing clevudine and adefovir dipivoxil
WO2012079035A1 (en) 2010-12-10 2012-06-14 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
EP3294745B1 (de) * 2015-05-08 2020-01-01 H. Hoffnabb-La Roche Ag Neuartige oxathiolan-carbonsäuren und derivate zur behandlung und prophylaxe von virusinfektionen
CN105943547B (zh) * 2016-05-23 2018-01-19 北京慧宝源生物技术股份有限公司 抗hbv的药物组合物及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
EP0141927B1 (de) * 1983-08-18 1991-10-30 Beecham Group Plc Antivirale Guanin-Derivate
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
JPH03501253A (ja) 1987-09-22 1991-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア エイズ(aids)治療を目的とするリポソームによるヌクレオシド類似物質
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8904855D0 (en) * 1989-03-03 1989-04-12 Beecham Group Plc Pharmaceutical treatment
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
EP0531452A4 (en) 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
US5674869A (en) * 1990-07-07 1997-10-07 Beecham Group Plc Pharmaceutical treatment
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
CA2112803A1 (en) 1991-07-12 1993-01-21 Karl Y. Hostetler Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
JPH08510236A (ja) 1993-05-12 1996-10-29 カール ワイ. ホステトラー 局所使用のためのアシクロビル誘導体
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
WO1998023285A1 (en) * 1996-11-29 1998-06-04 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
EA005097B1 (ru) * 1997-03-19 2004-10-28 Эмори Юниверсити Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гепатита-b
IL142910A0 (en) * 1998-11-02 2002-04-21 Triangle Pharmaceuticals Inc Combination therapy to treat hepatitis b virus

Also Published As

Publication number Publication date
WO2000025797A1 (en) 2000-05-11
EP1382343A1 (de) 2004-01-21
IL193148A0 (en) 2009-02-11
EP1380303B1 (de) 2008-09-17
AU1810600A (en) 2000-05-22
CN1666742A (zh) 2005-09-14
PT1380303E (pt) 2008-11-03
DE69942042D1 (de) 2010-04-01
DE69923338T2 (de) 2006-04-06
US6528515B1 (en) 2003-03-04
CY1110629T1 (el) 2015-04-29
EP1124562B1 (de) 2005-01-19
JP2011079840A (ja) 2011-04-21
EP1380303A1 (de) 2004-01-14
CN1891221A (zh) 2007-01-10
EP1382343B1 (de) 2010-02-17
EP1124562A1 (de) 2001-08-22
PT1382343E (pt) 2010-03-10
ES2237189T3 (es) 2005-07-16
ES2338642T3 (es) 2010-05-11
KR20010082282A (ko) 2001-08-29
DK1382343T3 (da) 2010-04-26
IL142910A0 (en) 2002-04-21
US20030158150A1 (en) 2003-08-21
US20090247487A1 (en) 2009-10-01
IL193148A (en) 2011-09-27
ATE457734T1 (de) 2010-03-15
JP2002528508A (ja) 2002-09-03
DE69923338D1 (de) 2005-02-24
ES2314157T3 (es) 2009-03-16
KR100632520B1 (ko) 2006-10-09
CN1329497A (zh) 2002-01-02
DE69939604D1 (de) 2008-10-30
DK1380303T3 (da) 2008-12-01
IL142910A (en) 2009-06-15
CN1173705C (zh) 2004-11-03
US7572800B2 (en) 2009-08-11
ATE408410T1 (de) 2008-10-15
ATE287268T1 (de) 2005-02-15
HK1062146A1 (en) 2004-10-21
CY1108635T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
CY1110629T1 (el) Πολυθεραπεια για θεραπευτικη αγωγη ιου ηπατιτιδας β
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
ATE207355T1 (de) Behandlung von hyperproliferativen gefässerkrankungen
PL296460A1 (en) Method of obtaining a trombine preparation effectively protected against viruses
ATE395922T1 (de) Lipid-analoge zur behandlung von viralen infektionen
ATE329598T1 (de) 1,3-oxathiolane zur behandlung von hepatitis
SG132498A1 (en) Beta-l-2æ-deoxy-nucleosides for the treatment of hepatitis b
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69029528D1 (de) Verwendung von funkionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie
DE69932154D1 (de) Verwendung von n-substituirten-1,5-dideoxy-1,5-imino-d-glucitolen zur behandlung von hepatitis infektionen
BR9808221A (pt) Método de tratamento de tumor.
DE60237721D1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
DE60123042D1 (de) L-fmau zur behandlung von hepatitis-delta-virus-infizierung
SI0948967T1 (en) Treatment of viral disease in swine
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DE69210737D1 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
ZA908933B (en) Prevention of glycoprotein enveloped virus infectivity by quinolyloxazole-2-ones
DE3684825D1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
EA200001065A1 (ru) Применение фосфорорганических соединений для терапевтического и профилактического лечения инфекций